{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["carcinoma colo-rettale avanzato","Colorectal neoplasms malignant"],"disease":["Colorectal Neoplasms Malignant","Carcinoma Colo-rettale Avanzato"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2520633"],"location":["Italy"],"study_start_month":["11"],"keyword":["ERBITUX*INFUS 1FL 50ML 2MG/ML","MITOMYCIN C*INIET 1FL 10MG","CAMPTO*1FL 100MG/5ML"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Cetuximab + Irinotecano vs chemoterapia standard nel carcinoma colo-rettale avanzato pretrattato non resecabile esprimente EGFR","description":"Primary objectives: Sopravvivenza globale","dates":{"creation":"2006-11-15"},"accession":"2520633","cross_references":{"EU Clinical Trials Register":["2006-004849-42"]}}